- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
Report Code: PHM049A, Published: May 2006, Analyst: Melissa Elder
INTRODUCTION
Annually, more than 3.5 million people die of influenza, and with the threat of a pandemic government agencies and disease prevention organizations are devoted to gain control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next year will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control.
This new report from BCC Research is designed to be a helpful business tool that will provide thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. data. The report identifies markets in general segments: Vaccines/ Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis. Additionally, the study covers some of most significant issues and trends and market factors.SCOPE OF STUDY
This report:
- Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics.Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2010.Identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis.Covers some of the most significant issues, trends and market factors.Profiles the top companies and major players in the market.
METHODOLOGY
The information for this BCC Research report was obtained through primary and secondary data-collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments, and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature, and various business journals that have emphasis on influenza products, technology and related information.
Market data for this report pertains to the worldwide market, with U.S. data included. All information is displayed using U.S. dollars at the manufacturers' level. The base year of the report is 2005, with historical data provided for 2003 and 2004, and forecast data provided through 2010. Historical, base year, and forecast data are provided for each market segment of the report. Average annual growth rates are determined through a complication of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the 2005 base year.ANALYST CREDENTIALS
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over-the-counter pharmaceuticals and various healthcare-related topics. Ms. Elder has worked in the healthcare field for the past eleven years and has a wide range of experience.
Report Code: PHM049A, Published: May 2006, Analyst: Melissa Elder
RELATED BCC REPORTS
- B-209 Point of Care Diagnostics
- B-175 Animal Therapeutics and Diagnostics
- B-202 Pandemic Control: Resistant Organisms and Emerging Threats
- B-185 Medical Diagnostic Reagents, Carriers and Other Consumables
- C-171R The Worldwide Market for Prophylactic and Therapeutic Vaccines
- C-202R New Developments in Therapeutic Enzyme Inhibitors and Blockers
- B-155 Antibiotic Resistance: New Products and Strategies
- B-161 The Market for Prescription Antiviral Drugs
- B-139 Respiratory Drugs: Where To?
- B-112 Medical Anti-Infective Agents
- B-114 Protein Drugs: Manufacturing Technologies
- C-171 The New & Re-emerging Market for Human Vaccines
Report Code: PHM049A, Published: May 2006, Analyst: Melissa Elder
Table of Contents
